. Author manuscript; available in PMC: 2018 Apr 1.

Published in final edited form as: Drug Discov Today. 2016 Dec 23;22(4):665–680. doi: 10.1016/j.drudis.2016.12.009

Table 2.

Examples of current ongoing clinical trials utilizing HA as excipient/targeting ligand in cancer drug delivery

Year (NCT)	Clinical trial	Intervention	Condition
2014 (NCT02216487)	Trial of FOLF(HA)Iri with cetuximab in mCRC	HA-Irinotecan	mCRC
2016 (NCT02753595)	Study of eribulin mesylate in combination with PEGylated recombinant human hyaluronidase (PEGPH20) versus eribulin mesylate alone in subjects with (HER2)-negative, high-hyaluronan (HA) metastatic breast cancer (MBC)	Drug: eribulin mesylate; biologic: PEGylated recombinant human hyaluronidase (PEGPH20)	Metastatic breast cancer
2015 (NCT02346370)	A Phase 1b study of PEGylated recombinant human hyaluronidase (PEGPH20) combined with docetaxel in subjects with recurrent previously treated locally advanced or metastatic non-small lung cancer	Drug: PEGPH20; drug: docetaxel	Non-small cell lung cancer
2016 (NCT02715804)	A study of PEGylated recombinant human hyaluronidase in combination with Nab-PTX plus gemcitabine compared with placebo plus Nab- PTX and gemcitabine in participants with hyaluronan-high stage IV previously untreated pancreatic ductal adenocarcinoma	Biological: PEGylated recombinant human hyaluronidase (PEGPH20); drug: placebo; drug: Nab-PTX; drug: gemcitabine	Pancreatic ductal adenocarcinoma
2016 (NCT02910882)	PEGPH20 plus gemcitabine with radiotherapy in patients with localized, unresectable pancreatic cancer	Drug: PEGylated recombinant human hyaluronidase (PEGPH20); drug: Gemcitabine; radiation: radiation	Pancreatic adenocarcinoma (nonresectable)